To expand these analyses, we examined the collection of 10 EGFR mutant cancer samples (from 9 patients) that underwent transformation to SCLC at the time of acquired resistance as well as the 11 resistant controls that had maintained NSCLC histology (Supplementary Table 1). The gene discussed is EGFR; the disease is small cell lung carcinoma.